A Multisite, 6-Month, Open-Label Study of Maintenance Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression

被引:1
|
作者
Garzon, Juan F. [1 ]
Elmaadawi, Ahmed Z. [2 ,3 ]
Aaronson, Scott T. [4 ]
Schrodt Jr, G. Randolph [5 ]
Holbert, Richard C. [6 ]
Zuckerman, Seth [7 ]
Demitrack, Mark A. [8 ]
Strawn, Jeffrey R. [9 ]
Croarkin, Paul E. [1 ]
机构
[1] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55902 USA
[2] Banner Univ, Med Ctr, Dept Psychiat, Phoenix, AZ USA
[3] Univ Arizona, Coll Med, Dept Psychiat, Phoenix, AZ USA
[4] Sheppard Pratt, Inst Adv Diagnost & Therapeut, Towson, MD USA
[5] Integrat Psychiat, Louisville, KY USA
[6] Univ Florida, Shands Psychiat Hosp, Psychiat, Gainesville, FL USA
[7] Neuronetics Inc, Biostat & Res, Malvern, PA USA
[8] Trevena Inc, Chesterbrook, PA USA
[9] Univ Cincinnati, Psychiat & Behav Neurosci, Cincinnati, OH USA
关键词
adolescent; maintenance TMS; transcranial magnetic stimulation; treatment-resistant depression; RELAPSE-PREVENTION; MAJOR DEPRESSION; TMS; NEUROMODULATION; THERAPY; LONG;
D O I
10.1089/cap.2024.0067
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: Transcranial magnetic stimulation (TMS) is a promising intervention for adolescents with treatment-resistant depression (TRD). However, the durability of TMS-related improvement in adolescents is unclear. This 6-month study followed adolescents with TRD who had responded to TMS and provided TMS retreatment for adolescents with a partial relapse.Methods: The study enrolled adolescents (12-21 years) with TRD who had at least a partial response to sham or active TMS in a randomized controlled trial. Partial response was defined as >= 25% reduction of Hamilton Depression Rating Scale-24 (HAMD24). Participants with a partial relapse (>= 1 point increase in Clinical Global Impression-Severity) received retreatment with daily 10 Hz TMS sessions until depressive symptom severity returned to the baseline score or after 30 TMS treatments.Results: There were 84 eligible participants, 66 were enrolled, and 41 completed the 6-month study. Twenty-eight participants (42%) were retreated with TMS. TMS retreatment courses had a mean of 22 sessions. At the 6-month follow-up, the complete sample exhibited reduced depressive symptoms (mean HAMD24 of 5.24) compared with baseline at entry into follow-up (mean HAMD24 of 8.21). Baseline depressive symptom severity was positively correlated with the risk of partial relapse, while the number of previous TMS interventions showed no correlation with the risk of partial relapse. TMS was well tolerated.Conclusions: This is the largest, long-term follow-up study with TMS retreatment for adolescents with TRD. These findings demonstrate the feasibility and clinical effects of a TMS retreatment protocol for adolescents with TRD, following a standard course of acute TMS.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 50 条
  • [21] TRANSCRANIAL MAGNETIC STIMULATION REINTRODUCTION TO MAINTAIN CLINICAL BENEFIT FOR ADOLESCENTS WITH TREATMENT-RESISTANT DEPRESSION
    Garzon, Juan Felipe
    Elmaadawi, Ahmed Z.
    Aaronson, Scott T.
    Schrodt, Randy
    Holbert, Richard C.
    Zuckerman, Seth
    Demitrack, Mark A.
    Strawn, Jeffrey R.
    Croarkin, Paul E.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2023, 62 (10): : S319 - S319
  • [22] Transcranial direct current stimulation in treatment-resistant obsessive-compulsive disorder: An open-label pilot study
    Bation, Remy
    Poulet, Emmanuel
    Haesebaert, Frederic
    Saoud, Mohamed
    Brunelin, Jerome
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2016, 65 : 153 - 157
  • [23] Open Trial of Repetitive Transcranial Magnetic Stimulation in Youth With Treatment-Resistant Major Depression
    MacMaster, Frank
    Croarkin, Paul
    Wilkes, T. Christopher
    McLellan, Quinn
    Langevin, Lisa Marie
    Jaworska, Natalia
    Swansburg, Rose
    Jasaui, Yamile
    Zewdie, Ephrem
    Ciechanski, Patrick
    Kirton, Adam
    BIOLOGICAL PSYCHIATRY, 2018, 83 (09) : S389 - S390
  • [24] Repetitive transcranial magnetic stimulation of the supplementary motor area in treatment-resistant obsessive-compulsive disorder: An open-label pilot study
    Lee, Young-Ji
    Koo, Bon-Hoon
    Seo, Wan-Seok
    Kim, Hye-Geum
    Kim, Ji-Yean
    Cheon, Eun-Jin
    JOURNAL OF CLINICAL NEUROSCIENCE, 2017, 44 : 264 - 268
  • [25] ACCELERATED REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION FOR TREATMENT-RESISTANT DEPRESSION
    Holtzheimer, Paul E., III
    McDonald, William M.
    Mufti, Mustafa
    Kelley, Mary E.
    Quinn, Sinead
    Corso, German
    Epstein, Charles M.
    DEPRESSION AND ANXIETY, 2010, 27 (10) : 960 - 963
  • [26] Treatment-resistant depression responds to repetitive transcranial magnetic stimulation
    Nature Clinical Practice Neurology, 2007, 3 (1): : 6 - 6
  • [27] The Role of Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Review
    Lee, Jonathan C.
    Blumberger, Daniel M.
    Fitzgerald, Paul B.
    Daskalakis, Zafiris J.
    Levinson, Andrea J.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (36) : 5846 - 5852
  • [28] Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression
    Jerath, Aarti U.
    Oldak, Sean E.
    Parrish, Manasi S.
    Zaydlin, Michelle
    Martin, Stephon
    Brown, Keneil
    Cara, Valentina
    Coffey, Barbara J.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2023, 33 (07) : 297 - 303
  • [29] Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
    Carhart-Harris, Robin L.
    Bolstridge, Mark
    Rucker, James
    Day, Camilla M. J.
    Erritzoe, David
    Kaelen, Mendel
    Bloomfield, Michael
    Rickard, James A.
    Forbes, Ben
    Feilding, Amanda
    Taylor, David
    Pilling, Steve
    Curran, Valerie H.
    Nutt, David J.
    LANCET PSYCHIATRY, 2016, 3 (07): : 619 - 627
  • [30] Dextromethorphan-Quinidine in Treatment-Resistant Depression: An Open-Label Pilot Study
    Wang, Philip
    Yavi, Mani
    Park, Lawrence
    Zarate, Carlos
    BIOLOGICAL PSYCHIATRY, 2023, 93 (09) : S177 - S178